Evidence map›Paper›PMID 41198655›Full record

Trial reportNature communications2025

An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial.

Meagan E Deming, Franklin R Toapanta, Marcela Pasetti, Hana Golding, Surender Khurana, Tarek Hamouda, Ali Fattom, Yuanyuan Liang, Sharon M Tennant, Megan F McGilvray and 11 more

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Meagan E Deming *Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2574-0542
Franklin R Toapanta *Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9439-0828
Marcela PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Hana GoldingDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration, Silver Spring, MD, USA.
Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0002-0593-7965
Tarek HamoudaBlueWillow Biologics, Inc., Ann Arbor, MI, USA.
Ali FattomBlueWillow Biologics, Inc., Ann Arbor, MI, USA.
Yuanyuan LiangCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Sharon M TennantCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Megan F McGilvrayCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Paula J BernalCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0009-0002-2421-302X
Jennifer J OshinskyCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6919-6780
Shrimati DattaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Jasnehta Permala BoothCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Lynda CoughlanCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9880-6560
Kathleen M NeuzilCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Chad D CostleyBlueWillow Biologics, Inc., Ann Arbor, MI, USA.
Karen L KotloffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-1808-6431
Marcelo B SzteinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Justin R OrtizCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. jortiz@som.umaryland.edu.ORCID http://orcid.org/0000-0002-3138-5965
rH5 Writing Group

Funding

Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccineR01AI148369 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI COUGHLAN, LYNDA · 2022 to 2025
$2.0M
A Phase I Randomized Clinical Trial of a Novel Mucosal Recombinant H5 Influenza Vaccine with Nanoemulsion Adjuvant Followed by Parenteral Boost of Licensed Inactivated Influenza A H5N1 VaccineU01AI148081 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ORTIZ, JUSTIN R. · 2020 to 2023
$1.8M
Characterization of seasonal CoV immunity and operationalization of a novel controlled human infection model for the betacoronavirus OC43K08AI170950 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Meagan Elise Deming · 2023 to 2026
$635k
Urine metabolomics to estimate internal clock timeR21NR018974 · NINR · BRIGHAM AND WOMEN'S HOSPITAL · PI ST HILAIRE, MELISSA APRIL · 2019 to 2020
$492k
NIAID NIH HHS K08 AI170950NIAID NIH HHS R01 AI148369NIAID NIH HHS U01 AI148081NINR NIH HHS R21 NR018974U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (BARDA) HHSO100200600021CU.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) K08A170950U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI148369U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U01AI148081
6 · The paper itself

Abstract

Mucosal influenza vaccines may provide improved protection against infection and transmission, but their development is hindered by absence of immune correlates of protection. Here, we report a randomized, controlled phase I trial of a recombinant influenza A/H5 (A/Indonesia/05/2005, clade 2.1) hemagglutinin vaccine formulated with a nanoemulsion adjuvant (W

Indexed as

Hemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H5N1 SubtypeInfluenza, HumanInfluenza VaccinesAdjuvants, ImmunologicAdjuvants, VaccineAdministration, IntranasalAdolescentAdultAntibodies, ViralFemaleHemagglutination Inhibition TestsHumansMaleMiddle AgedVaccines, SyntheticAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesVaccines, Synthetic

Identifiers

PMID41198655
PMCPMC12592354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.